Market Research Report

Global Pyogenic Granuloma Treatment Market Report By Drug Classification (Antibiotics, Antimalarials, Corticosteroid, Ointments, Others), By Treatment (Medication, Surgery, Dialysis, Others), By Route of Administration (Oral, Parenteral, Others), By End-Users (Hospitals, Specialty Clinics, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) And By Regions - Industry Trends, Size, Share, Growth, Estimation and Forecast, 2021-2028

ID:VMR11218080
April 2022
Report Formats: Report Formats
The global demand for Pyogenic Granuloma Treatment Market is presumed to reach the market size of nearly USD XX MN by 2028 from USD XX MN in 2021 with a CAGR of XX% under the study period 2022 - 2028.

Pyogenic granuloma refers to a small red lesion or benign growth on the surface of the skin, and pyogenic granuloma treatment refers to the removal of the lesions. There are four ways to treat pyogenic granuloma. It can be removed with the help of chemicals such as Trichloroacetic acid (TCA), silver nitrate and phenol. Full-thickness surgical excision is another effective way to remove pyogenic granuloma, and it can be removed with laser surgery as well. Scraping off the lesions with the help of a curette and cauterizing the site to reduce the likelihood of regrowth is another treatment option. Pyogenic granuloma can also be treated topically with cryotherapy, intralesional steroid injection, Imiquimod cream 5% and Timolol gel 0.5%.

Market Dynamics

The global pyogenic granuloma treatment market is predicted to register impressive growth during the forecast period. The key factor driving the target market is the increasing incidence of pyogenic granuloma throughout the world. The market is also majorly driven by the fact that pharmaceutical companies are making a significant amount of investment in research and development activities with an aim to introduce new therapies and treatment options. High occurrence of side effects of different types of medications, for example oral retinoid medications, will positively impact the market. Furthermore, the market will be favored by growing awareness related to tumors. However, it takes long to obtain drug approvals, and this is a major restraining factor for pyogenic granuloma treatment market growth.

The research report covers Porter’s Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of pyogenic granuloma treatment. The growth and trends of pyogenic granuloma treatment industry provide a holistic approach to this study. 

Market Segmentation

This section of the pyogenic granuloma treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities. 

By Drug Classification
  • Antibiotics
  • Antimalarials
  • Corticosteroid
  • Ointments
  • Others

By Treatment
  • Medication
  • Surgery
  • Dialysis
  • Others

By Route Of Administration
  • Oral
  • Parenteral
  • Others

By End-Users
  • Hospitals
  • Specialty Clinics
  • Others

By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

Regional Analysis

This section covers the regional outlook, which accentuates current and future demand for the Pyogenic Granuloma Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

Global Pyogenic Granuloma Treatment Market Share by Region (Representative Graph)

Global Pyogenic Granuloma Treatment Market Share
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the pyogenic granuloma treatment market include Clinigen Group plc, Orchard Therapeutics plc, Généthon, Horizon Therapeutics plc, ViroMed. Co. Ltd, Bellicum Pharmaceuticals, Inc., Pfizer Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Lonza, GlaxoSmithKline plc., Eli Lilly and Company, Johnson & Johnson Services, Inc., Merck KGaA, Smith & Nephew, JCR Pharmaceuticals Co. Ltd, MaxCyte, Inc., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., and Antares Pharma among others. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

METHODOLOGY:

This market research report has been produced by gathering information based on primary and secondary research. Secondary research has been done using various sources, including (but not limited to) Company Websites, Paid Data Sources, Technical Journals, Financial Reports, SEC Filings, and other different industry publications. Additionally, our team conducts extensive primary research with key industry participants to gather first-hand data. The data is then analyzed and validated by industry experts.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE
       1.1. Report Description
           1.1.1. Objective
           1.1.2. Target Audience
           1.1.3. Unique Selling Proposition (USP) & offerings
       1.2. Research Scope
       1.3. Research Methodology
           1.3.1. Market Research Process
           1.3.2. Market Research Methodology
 
2 . EXECUTIVE SUMMARY
       2.1. Highlights of Market
       2.2. Global Market Snapshot
 
3 . PYOGENIC GRANULOMA TREATMENT – INDUSTRY ANALYSIS
       3.1. Introduction - Market Dynamics
       3.2. Market Drivers
       3.3. Market Restraints
       3.4. Opportunities
       3.5. Industry Trends
       3.6. Porter’s Five Force Analysis
       3.7. Market Attractiveness Analysis
           3.7.1 Market Attractiveness Analysis By Drug Classification
           3.7.2 Market Attractiveness Analysis By Treatment
           3.7.3 Market Attractiveness Analysis By Route Of Administration
           3.7.4 Market Attractiveness Analysis By End-Users
           3.7.5 Market Attractiveness Analysis By Distribution Channel
           3.7.6 Market Attractiveness Analysis By Region
 
4 . VALUE CHAIN ANALYSIS
       4.1. Value Chain Analysis
       4.2. Raw Material Analysis
           4.2.1. List of Raw Materials
           4.2.2. Raw Material Manufactures List
           4.2.3. Price Trend of Key Raw Materials
       4.3. List of Potential Buyers
       4.4. Marketing Channel
           4.4.1. Direct Marketing
           4.4.2. Indirect Marketing
           4.4.3. Marketing Channel Development Trend
 
5 IMPACT ANALYSIS OF COVID-19 OUTBREAK
       5.1. Impact Analysis of Covid-19 Outbreak
           5.1.1. Direct Impact on Production
           5.1.2. Supply Chain and Market Disruption
           5.1.3. Financial Impact on Firms and Financial Markets
       5.2. COVID-19 Impact Analysis by Production, Import, Export and Demand
       5.3. Market: Pre V/S Post COVID-19
       5.4. Estimated Impact of the Coronavirus (COVID-19) Epidemic 
       5.5. COVID-19: Micro and Macro Factor Analysis
 
6 . GLOBAL PYOGENIC GRANULOMA TREATMENT MARKET ANALYSIS BY DRUG CLASSIFICATION
       6.1 Overview by Drug Classification
       6.2 Historical and Forecast Data
       6.3 Analysis by Drug Classification
       6.4 Antibiotics Historic and Forecast Sales by Regions
       6.5 Antimalarials Historic and Forecast Sales by Regions
       6.6 Corticosteroid Historic and Forecast Sales by Regions
       6.7 Ointments Historic and Forecast Sales by Regions
       6.8 Others Historic and Forecast Sales by Regions
 
7 . GLOBAL PYOGENIC GRANULOMA TREATMENT MARKET ANALYSIS BY TREATMENT
       7.1 Overview by Treatment
       7.2 Historical and Forecast Data
       7.3 Analysis by Treatment
       7.4 Medication Historic and Forecast Sales by Regions
       7.5 Surgery Historic and Forecast Sales by Regions
       7.6 Dialysis Historic and Forecast Sales by Regions
       7.7 Others Historic and Forecast Sales by Regions
 
8 . GLOBAL PYOGENIC GRANULOMA TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
       8.1 Overview by Route Of Administration
       8.2 Historical and Forecast Data
       8.3 Analysis by Route Of Administration
       8.4 Oral Historic and Forecast Sales by Regions
       8.5 Parenteral Historic and Forecast Sales by Regions
       8.6 Others Historic and Forecast Sales by Regions
 
9 . GLOBAL PYOGENIC GRANULOMA TREATMENT MARKET ANALYSIS BY END-USERS
       9.1 Overview by End-Users
       9.2 Historical and Forecast Data
       9.3 Analysis by End-Users
       9.4 Hospitals Historic and Forecast Sales by Regions
       9.5 Specialty Clinics Historic and Forecast Sales by Regions
       9.6 Others Historic and Forecast Sales by Regions
 
10 . GLOBAL PYOGENIC GRANULOMA TREATMENT MARKET ANALYSIS BY DISTRIBUTION CHANNEL
       10.1 Overview by Distribution Channel
       10.2 Historical and Forecast Data
       10.3 Analysis by Distribution Channel
       10.4 Hospital Pharmacy Historic and Forecast Sales by Regions
       10.5 Retail Pharmacy Historic and Forecast Sales by Regions
       10.6 Others Historic and Forecast Sales by Regions
 
11 . GLOBAL PYOGENIC GRANULOMA TREATMENT MARKET ANALYSIS BY GEOGRAPHY
       11.1. Top  Company Share Analysis
       11.2. Introduction
       11.3. North America Sales Analysis
           11.3.1. Overview, Historic and Forecast Sales Analysis
           11.3.2. North America By Segment Sales Analysis
           11.3.3. North America By Country Sales Analysis
           11.3.4. United State Sales Analysis
           11.3.5. Canada Sales Analysis
           11.3.6. Mexico Sales Analysis
       11.4. Europe Sales Analysis
           11.4.1. Overview, Historic and Forecast Sales Analysis
           11.4.2. Europe by Segment Sales Analysis
           11.4.3. Europe by Country Sales Analysis
           11.4.4. United Kingdom Sales Analysis
           11.4.5. France Sales Analysis
           11.4.6. Germany Sales Analysis
           11.4.7. Italy Sales Analysis
           11.4.8. Russia Sales Analysis
           11.4.9. Rest Of Europe Sales Analysis
       11.5. Asia Pacific Sales Analysis
           11.5.1. Overview, Historic and Forecast Sales Analysis
           11.5.2. Asia Pacific by Segment Sales Analysis
           11.5.3. Asia Pacific by Country Sales Analysis
           11.5.4. China Sales Analysis
           11.5.5. India Sales Analysis
           11.5.6. Japan Sales Analysis
           11.5.7. South Korea Sales Analysis
           11.5.8. Australia Sales Analysis
           11.5.9. Rest Of Asia Pacific Sales Analysis
       11.6. Latin America Sales Analysis
           11.6.1. Overview, Historic and Forecast Sales Analysis
           11.6.2. Latin America by Segment Sales Analysis
           11.6.3. Latin America by Country Sales Analysis
           11.6.4. Brazil Sales Analysis
           11.6.5. Argentina Sales Analysis
           11.6.6. Peru Sales Analysis
           11.6.7. Chile Sales Analysis
           11.6.8. Rest of Latin America Sales Analysis
       11.7. Middle East & Africa Sales Analysis
           11.7.1. Overview, Historic and Forecast Sales Analysis
           11.7.2. Middle East & Africa by Segment Sales Analysis
           11.7.3. Middle East & Africa by Country Sales Analysis
           11.7.4. Saudi Arabia Sales Analysis
           11.7.5. UAE Sales Analysis
           11.7.6. Israel Sales Analysis
           11.7.7. South Africa Sales Analysis
           11.7.8. Rest Of Middle East And Africa Sales Analysis
 
12 . COMPETITIVE LANDSCAPE OF THE PYOGENIC GRANULOMA TREATMENT COMPANIES
       12.1. Pyogenic Granuloma Treatment Market Competition
       12.2. Partnership/Collaboration/Agreement
       12.3. Merger And Acquisitions
       12.4. New Product Launch
       12.5. Other Developments
 
13 . COMPANY PROFILES OF PYOGENIC GRANULOMA TREATMENT INDUSTRY
       13.1. Company Share Analysis
       13.2. Market Concentration Rate
       13.3. Clinigen Group plc
           13.3.1. Company Overview
           13.3.2. Company Revenue
           13.3.3. Products
           13.3.4. Recent Developments
       13.4. Orchard Therapeutics plc
           13.4.1. Company Overview
           13.4.2. Company Revenue
           13.4.3. Products
           13.4.4. Recent Developments
       13.5. Généthon
           13.5.1. Company Overview
           13.5.2. Company Revenue
           13.5.3. Products
           13.5.4. Recent Developments
       13.6. Horizon Therapeutics plc
           13.6.1. Company Overview
           13.6.2. Company Revenue
           13.6.3. Products
           13.6.4. Recent Developments
       13.7. ViroMed. Co. Ltd
           13.7.1. Company Overview
           13.7.2. Company Revenue
           13.7.3. Products
           13.7.4. Recent Developments
       13.8. Bellicum Pharmaceuticals Inc.
           13.8.1. Company Overview
           13.8.2. Company Revenue
           13.8.3. Products
           13.8.4. Recent Developments
       13.9. Pfizer Inc.
           13.9.1. Company Overview
           13.9.2. Company Revenue
           13.9.3. Products
           13.9.4. Recent Developments
       13.10. F. Hoffmann-La Roche Ltd
           13.10.1. Company Overview
           13.10.2. Company Revenue
           13.10.3. Products
           13.10.4. Recent Developments
       13.11. Novartis AG
           13.11.1. Company Overview
           13.11.2. Company Revenue
           13.11.3. Products
           13.11.4. Recent Developments
       13.12. Lonza
           13.12.1. Company Overview
           13.12.2. Company Revenue
           13.12.3. Products
           13.12.4. Recent Developments
       13.13. GlaxoSmithKline plc.
           13.13.1. Company Overview
           13.13.2. Company Revenue
           13.13.3. Products
           13.13.4. Recent Developments
       13.14. Eli Lilly and Company
           13.14.1. Company Overview
           13.14.2. Company Revenue
           13.14.3. Products
           13.14.4. Recent Developments
       13.15. Johnson & Johnson Services Inc.
           13.15.1. Company Overview
           13.15.2. Company Revenue
           13.15.3. Products
           13.15.4. Recent Developments
       13.16. Merck KGaA
           13.16.1. Company Overview
           13.16.2. Company Revenue
           13.16.3. Products
           13.16.4. Recent Developments
       13.17. Smith & Nephew
           13.17.1. Company Overview
           13.17.2. Company Revenue
           13.17.3. Products
           13.17.4. Recent Developments
       13.18. JCR Pharmaceuticals Co. Ltd
           13.18.1. Company Overview
           13.18.2. Company Revenue
           13.18.3. Products
           13.18.4. Recent Developments
       13.19. MaxCyte Inc.
           13.19.1. Company Overview
           13.19.2. Company Revenue
           13.19.3. Products
           13.19.4. Recent Developments
       13.20. Fresenius Kabi AG
           13.20.1. Company Overview
           13.20.2. Company Revenue
           13.20.3. Products
           13.20.4. Recent Developments
       13.21. Sun Pharmaceutical Industries Ltd.
           13.21.1. Company Overview
           13.21.2. Company Revenue
           13.21.3. Products
           13.21.4. Recent Developments
       13.22. Antares Pharma
           13.22.1. Company Overview
           13.22.2. Company Revenue
           13.22.3. Products
           13.22.4. Recent Developments
       13.23. Others
           13.23.1. Company Overview
           13.23.2. Company Revenue
           13.23.3. Products
           13.23.4. Recent Developments    
 
 *Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies
 
LIST OF TABLES
 

  •  Market Snapshot
  •  Drivers : Impact Analysis
  •  Restraints : Impact Analysis
  •  List of Raw Material
  •  List of Raw Material Manufactures
  •  List of Potential Buyers
  •  COVID-19 Impact Analysis by Production, Import, Export and Demand
  •  Pre V/S Post COVID-19
  •  Estimated Impact Of The Coronavirus (Covid-19) Epidemic
  •  COVID-19: Micro and Macro Factor Analysis
  •  Analysis by Drug Classification (USD MN)
  •  Antibiotics Market Sales by Geography (USD MN)
  •  Antimalarials Market Sales by Geography (USD MN)
  •  Corticosteroid Market Sales by Geography (USD MN)
  •  Ointments Market Sales by Geography (USD MN)
  •  Others Market Sales by Geography (USD MN)
  •  Analysis Market by Treatment (USD MN)
  •  Medication Market Sales by Geography (USD MN)
  •  Surgery Market Sales by Geography (USD MN)
  •  Dialysis Market Sales by Geography (USD MN)
  •  Others Market Sales by Geography (USD MN)
  •  Analysis by Route Of Administration (USD MN)
  •  Oral Market Sales by Geography (USD MN)
  •  Parenteral Market Sales by Geography (USD MN)
  •  Others Market Sales by Geography (USD MN)
  •  Analysis by End-Users (USD MN)
  •  Hospitals Market Sales by Geography (USD MN)
  •  Specialty Clinics Market Sales by Geography (USD MN)
  •  Others Market Sales by Geography (USD MN)
  •  Analysis by Distribution Channel (USD MN)
  •  Hospital Pharmacy Market Sales by Geography (USD MN)
  •  Retail Pharmacy Market Sales by Geography (USD MN)
  •  Others Market Sales by Geography (USD MN)
  •  Global Pyogenic Granuloma Treatment Market Sales by Geography (USD MN)
  •  North America Market Analysis (USD MN)
  •  United State Market Analysis (USD MN)
  •  Canada Market Analysis (USD MN)
  •  Mexico Market Analysis (USD MN)
  •  Europe Market Analysis (USD MN)
  •  Europe Market Estimate by Country (USD MN)
  •  United Kingdom Market Analysis (USD MN)
  •  France Market Analysis (USD MN)
  •  Germany Market Analysis (USD MN)
  •  Italy Market Analysis (USD MN)
  •  Russia Market Analysis (USD MN)
  •  Spain Market Analysis (USD MN)
  •  Rest of Europe Market Analysis (USD MN)
  •  Asia Pacific Market Analysis (USD MN)
  •  China Market Analysis (USD MN)
  •  Japan Market Analysis (USD MN)
  •  India Market Analysis (USD MN)
  •  South Korea Market Analysis (USD MN)
  •  Australia Market Analysis (USD MN)
  •  Rest of Asia Pacific Market Analysis (USD MN)
  •  Latin America Market Analysis (USD MN)
  •  Brazil Market Analysis (USD MN)
  •  Argentina Market Analysis (USD MN)
  •  Peru Market Analysis (USD MN)
  •  Chile Market Analysis (USD MN)
  •  Rest of Latin America Market Analysis (USD MN)
  •  Middle East & Africa Market Analysis (USD MN)
  •  Saudi Arabia Market Analysis (USD MN)
  •  UAE Market Analysis (USD MN)
  •  Israel Market Analysis (USD MN)
  •  South Africa Market Analysis (USD MN)
  •  Rest of Middle East and Africa Market Analysis (USD MN)
  •  Partnership/Collaboration/Agreement
  •  Mergers And Acquisition
 
 LIST OF FIGURES
 
  •  Research Scope of Pyogenic Granuloma Treatment Report
  •  Market Research Process
  •  Market Research Methodology
  •  Global Pyogenic Granuloma Treatment Market Size, by Region (USD MN)
  •  Porters Five Forces Analysis
  •  Market Attractiveness Analysis by Drug Classification
  •  Market Attractiveness Analysis by Treatment
  •  Market Attractiveness Analysis by Route Of Administration
  •  Market Attractiveness Analysis by End-Users
  •  Market Attractiveness Analysis by Distribution Channel
  •  Market Attractiveness Analysis by Region
  •  Value Chain Analysis
  •  Global Market Analysis by Drug Classification (USD MN)
  •  Antibiotics Market Sales by Geography (USD MN)
  •  Antimalarials Market Sales by Geography (USD MN)
  •  Corticosteroid Market Sales by Geography (USD MN)
  •  Ointments Market Sales by Geography (USD MN)
  •  Others Market Sales by Geography (USD MN)
  •  Global Market Analysis by Treatment (USD MN)
  •  Medication Market Sales by Geography (USD MN)
  •  Surgery Market Sales by Geography (USD MN)
  •  Dialysis Market Sales by Geography (USD MN)
  •  Others Market Sales by Geography (USD MN)
  •  Global Market Analysis by Route Of Administration (USD MN)
  •  Oral Market Sales by Geography (USD MN)
  •  Parenteral Market Sales by Geography (USD MN)
  •  Others Market Sales by Geography (USD MN)
  •  Global Market Analysis by End-Users (USD MN)
  •  Hospitals Market Sales by Geography (USD MN)
  •  Specialty Clinics Market Sales by Geography (USD MN)
  •  Others Market Sales by Geography (USD MN)
  •  Global Market Analysis by Distribution Channel (USD MN)
  •  Hospital Pharmacy Market Sales by Geography (USD MN)
  •  Retail Pharmacy Market Sales by Geography (USD MN)
  •  Others Market Sales by Geography (USD MN)
  •  Global Market by Revenue
  •  North America Market by Revenue
  •  Europe Market by Revenue
  •  Asia Pacific Market by Revenue
  •  Latin America Market by Revenue
  •  Middle East & Africa Market by Revenue
  •  Recent Development in Industry
  •  Top  Company Share Analysis
 
 * Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Objectives of Study

  • Define and measure the global market
  • Volume or revenue forecast of the global market and its various sub-segments with respect to main geographies
  • Analyze and identify major market trends along with the factors driving or inhibiting the market growth
  • Study the company profiles of the major market players with their market share
  • Analyze competitive developments

Why Choose Us

Client First Policy
Excellent Quality
Robust After Sales Support
24/7 Email Support

Clients

Testimonials